Home » Stocks » HBIO

Harvard Bioscience, Inc. (HBIO)

Stock Price: $6.95 USD -0.06 (-0.86%)
Updated May 12, 2021 4:00 PM EDT - Market closed
Market Cap 280.10M
Revenue (ttm) 105.32M
Net Income (ttm) -3.96M
Shares Out 39.79M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE 24.27
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $6.95
Previous Close $7.01
Change ($) -0.06
Change (%) -0.86%
Day's Open 6.96
Day's Range 6.90 - 7.03
Day's Volume 327,763
52-Week Range 2.50 - 7.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Harvard Bioscience (HBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow...

5 days ago - Zacks Investment Research

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 66.67% and 6.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 days ago - Zacks Investment Research

Sales effectiveness, pre-clinical product demand and disciplined cost management result in improved revenues and margins

6 days ago - GlobeNewsWire

HOLLISTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2021 before the market opens on May 6, ...

3 weeks ago - GlobeNewsWire

Shares of Harvard Bioscience (NASDAQ:HBIO) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 0.00% year over year to $0.08, which beat the estimat...

2 months ago - Benzinga

On Wednesday, March 10, Harvard Bioscience (NASDAQ:HBIO) will release its latest earnings report. Decipher the announcement with Benzinga's help.

2 months ago - Benzinga

HOLLISTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2020 before the market opens on Marc...

2 months ago - GlobeNewsWire

HOLLISTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (“Harvard Bioscience”) today announced the refinancing of its debt with the closing of a new $65 million credi...

4 months ago - GlobeNewsWire

HOLLISTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will participate in The B...

5 months ago - GlobeNewsWire

Harvard Bioscience, Inc. (HBIO) CEO Jim Green on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

HOLLISTON, MA., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2020 before the market opens on Novemb...

6 months ago - GlobeNewsWire

HOLLISTON, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, President and CEO, will present at the Singular Research Compelling Values ...

7 months ago - GlobeNewsWire

Harvard Bioscience's (HBIO) CEO Jim Green on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

HOLLISTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2020 before the market opens on August...

9 months ago - GlobeNewsWire

Provides Update on Performance Against Previously Announced Strategic Plan Provides Update on Performance Against Previously Announced Strategic Plan

11 months ago - GlobeNewsWire

Harvard Bioscience, Inc.'s (HBIO) CEO Jim Green on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Drab Near-Term Prospects for Scientific Instruments Industry

Other stocks mentioned: MTD, PKI, WAT
1 year ago - Zacks Investment Research

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -125.00% and -15.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

The S&P 500 posted solid gains of 20.8%, 18% and 10.4% in the 12-month period after the first occurrence of SARS, MERS and Ebola back in 2003, 2013 and 2014, respectively.

Other stocks mentioned: BBW, GRBK, KGC, MEI
1 year ago - Zacks Investment Research

Engine Capital Withdraws Director Nomination Notice For 2020 Annual Meeting of Stockholders

1 year ago - GlobeNewsWire

Company will continue to manufacture and ship innovative products for global development and research throughout crisis Company will continue to manufacture and ship innovative products for global devel...

1 year ago - GlobeNewsWire

Harvard Bioscience, Inc.'s (HBIO) CEO Jim Green on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Scientific Instruments Industry Outlook: Prospects Look Good

Other stocks mentioned: MTD, PKI, WAT
1 year ago - Zacks Investment Research

Harvard Bioscience has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

Harvard Bioscience (HBIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

1 year ago - Zacks Investment Research

Harvard Bioscience, Inc. (HBIO) CEO Jim Green on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and -3.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

HOLLISTON, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that in connection with Yash Singh being named Executive Vice President, Cellular & Molecula...

1 year ago - GlobeNewsWire

HOLLISTON, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Yash Singh has been named Executive Vice President, Cellular & Molecular Technologies, ...

1 year ago - GlobeNewsWire

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

HOLLISTON, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Ken Olson has been named Vice President and General Manager, Pre-Clinical Systems (DSI)...

1 year ago - GlobeNewsWire

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Harvard Bioscience's (HBIO) CEO Jim Green on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Harvard Bioscience, Inc. (HBIO) CEO Jeffrey Duchemin on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -33.33% and -0.95%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

2 years ago - Zacks Investment Research

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

About HBIO

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equi... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Dec 7, 2000
Stock Exchange
NASDAQ
Ticker Symbol
HBIO
Full Company Profile

Financial Performance

In 2020, HBIO's revenue was $102.10 million, a decrease of -12.12% compared to the previous year's $116.18 million. Losses were -$7.81 million, 66.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for HBIO stock is "Strong Buy." The 12-month stock price forecast is 9.75, which is an increase of 40.29% from the latest price.

Price Target
$9.75
(40.29% upside)
Analyst Consensus: Strong Buy